Association between a history of mycobacterial infection and the risk of newly diagnosed Sjögren’s syndrome: A nationwide, population-based case-control study

Wen-Cheng Chao\textsuperscript{1,2,3}\textsuperscript{☯}, Ching-Heng Lin\textsuperscript{1}\textsuperscript{☯}, Tsai-Ling Liao\textsuperscript{1,4}, Yi-Ming Chen\textsuperscript{1,4,5,6}, Der-Yuan Chen\textsuperscript{4,5,6,7,8}\textsuperscript{*}, Hsin-Hua Chen\textsuperscript{1,4,5,6,7,9}\textsuperscript{*}

\textsuperscript{1}Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan, \textsuperscript{2}Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, \textsuperscript{3}Department of Business Administration, National Changhua University of Education, Changhua, Taiwan, \textsuperscript{4}Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, Chung-Hsing University, Taichung, Taiwan, \textsuperscript{5}Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, \textsuperscript{6}School of Medicine, National Yang-Ming University, Taipei, Taiwan, \textsuperscript{7}School of Medicine, Chung-Shan Medical University, Taichung, Taiwan, \textsuperscript{8}Department of Medical Education, Taichung Veterans General Hospital, Taichung, Taiwan, \textsuperscript{9}Institute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan

\textsuperscript{☯}These authors contributed equally to this work.

\textsuperscript{*}shc5555@hotmail.com (HHC); dychen@vgghtc.gov.tw (DYC)

Abstract

Objective

To address the association between a history of tuberculosis (TB) or nontuberculous mycobacterial (NTM) infection and the risk of newly diagnosed Sjögren’s syndrome (SS).

Methods

Using a nationwide, population-based, claims dataset, and after excluding those who had rheumatoid arthritis or systemic lupus erythematosus, we identified 5,751 newly diagnosed SS cases during 2007–2012, and compared them to 86,265 non-SS controls matched (1:15) for age, sex, and the year of first SS diagnosis date. The association between the risk of incident SS and a history of mycobacterial infection, including TB and NTM, was quantified by calculating odds ratios (ORs) with 95% confidence intervals (CIs) using conditional logistic regression analysis after adjustment for Charlson comorbidity index (CCI) and bronchiectasis.

Results

The mean age was 55±14 years, and the proportion of female gender was 87.8% in both newly diagnosed SS cases and non-SS controls. An association was observed between NTM infection (OR, 11.24; 95% CI, 2.37–53.24) and incident SS, but not between TB infection and incident SS (OR, 1.29; 95% CI, 0.97–1.71) after adjustment for CCI and bronchiectasis. The association between NTM and SS risk was remarkably strong among those aged
between 45 and 65 years (OR, 39.24; 95% CI, 3.97–387.75) and those without bronchiectasis (OR, 39.98; 95% CI, 3.83–376.92).

Conclusion

The study reveals a significant association of newly diagnosed SS with a history NTM infection, especially among individuals aged 40–65 years or those without bronchiectasis.

Introduction

Sjögren’s syndrome (SS) is estimated to affect approximately 1% of the general population and characterized to occur predominantly in middle-aged women, with a female-to-male ratio of approximately 9:1 [1]. SS majorly presented with an insidious onset of dry eyes and dry mouth, which might be ignored by patients [2, 3]. Therefore, the early diagnosis of SS has been shown to be difficult. Currently, the pathogenesis of SS remains elusive. Environmental, genetic and hormonal contributors appear to be involved [4]. Mycobacterial infections, including tuberculosis (TB) and nontuberculous mycobacterial (NTM) infection, are characterized by a subacute clinical course with a dysregulated granulomatous inflammation [5] and have been implicated in the development of autoimmunity [6, 7]. Moreover, both SS and NTM infection predominantly affect middle-aged women, indicating potential shared mechanisms in these two diseases [8–10]. An increased incidence of TB has been reported in subjects with SS [11]; however, whether TB or NTM infection is associated with the risk of SS is still unknown. The aim of this study is to investigate the association between mycobacterial infection and the risk of newly diagnosed SS using a population-based, longitudinal dataset.

Methods

Ethical statements

This study was approved by the Institutional Review Board of Taichung Veterans General Hospital Taiwan (IRB number: CE16251A). Informed consent was waived, given that the personal data obtained were anonymised before analysis.

Study design and data source

Taiwan launched a single-payer National Health Insurance (NHI) programme on March 1, 1995. As of 2015, 99.6% of Taiwan’s population were enrolled [12]. The National Health Insurance Research Data (NHIRD) is the database of the programme, containing registration files and original claim data for reimbursement. The Bureau of NHI (BNHI) managed the NHIRD and released the data for research purpose. In this retrospective study, the ambulatory, inpatient and enrollment data from the 2003–2012 NHIRD were used as discussed below to identify all patients with newly diagnosed SS. Moreover, in Taiwan, patients with certain major illnesses, such as cancer and certain autoimmune diseases, including SS, are issued a certificate of “catastrophic illness” and are hence exempt from copayment. In Taiwan, SS is diagnosed based on the classification criteria for SS proposed by the American–European Consensus Group in 2002 [13]. Patients are issued the certificate of catastrophic illness for SS if their SS diagnosis is validated by two qualified rheumatologists after a thorough review of patients’ medical records, laboratory data, and images. The NHIRD also contains a catastrophic illness enrollment file for patients with catastrophic illness certificates, namely the Registry for
Catastrophic Illness Patient Database (RCIPD). In the present study, SS patients were included only when they were found in the RCIPD. Additionally, the NHIRD constructed a representative database of 1,000,000 individuals randomly selected from all enrollees who received services in 2000 (Longitudinal Health Insurance Database, LHID2000). In this study, the data of the non-SS control group were extracted via matching SS cases for age, sex, and the year of first SS diagnosis date from this LHID 2000 database.

Study samples

**Incident SS cases identified from whole Taiwanese population.** SS patients were defined as having at least three ambulatory visits or one hospital admission with a diagnosis of SS [International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code 710.2] and a catastrophic illness certificate for SS. From the NHIRD, after exclusion of individuals who ever had a diagnosis of rheumatoid arthritis (RA) (ICD-9-CM code 714.0) or systemic lupus erythematosus (SLE) (ICD-9-CM code 710.0) during 2003–2013, we included all newly diagnosed SS cases from 2007 to 2012 as incident SS cases. The first date of visit with SS diagnosis was selected as the index date. The index year was the year of the index date.

**Matched non-SS controls selected from representative one million populations.** From LHID 2000, after exclusion of individuals who ever had ICD-9 codes for SS, RA or SLE during 2003–2013, we randomly selected non-SS controls, matching SS cases (1:15) for age, sex and the index year. Given that in non-SS controls, no diagnosis of SS was made, the index date used for non-SS controls was the day of first ambulatory visit for any reason in the index year.

**Definitions of mycobacterial infection.** Mycobacterial infection was identified by ICD-9-CM codes for TB: 010–018 and NTM: 031.0, 031.1, 031.2, 031.8, and 031.9 with the concurrent prescription of at least two anti-mycobacterial drugs within 12 months of the diagnosis. Anti-TB drug prescriptions included isoniazid, ethambutol, rifampin, pyrazinamide, streptomycin, prothionamide, kanamycin, amikacin, levofloxacin, ofloxacin, moxifloxacin, ciprofloxacin, and thioridazine [14]. Anti-NTM drugs consisted of amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline, ethambutol, imipenem, levofloxacin, meropenem, minocycline, moxifloxacin, rifabutin, rifampin, tigecycline, and streptomycin [15]. When TB and NTM infections were identified concurrently based on above definitions, we refer the diagnosis as TB if pyrazinamide was prescribed for longer than 28 days and as NTM if clarithromycin was prescribed for longer than 28 days; these criteria were based on the fact that these two drugs have mutually exclusive, condition-specific indications in TB and NTM.

**Comorbidities as potential confounders.** The presence of comorbidity was defined as having at least three ambulatory visits or one inpatient visit with a corresponding ICD-9-CM code within one year before the index date. The Charlson Comorbidity Index (CCI), as adapted by Deyo et al. [16], was used to assess the level of general comorbid conditions. Given that bronchiectasis appeared to be correlated with both SS and mycobacterial infection [17–19], we also included bronchiectasis, as indicated by the ICD-9-CM code 494, as a potential confounder.

**Statistical analysis.** The demographic data were presented as a mean ± standard deviation for continuous variables and as a percentage of patients in categorical variables. The differences were analyzed by using Student’s t-test for continuous variables and Pearson’s χ2 test for categorical variables. The history of mycobacterial infection in SS compared with those in controls was shown as an adjusted odds ratio (aOR) using multivariate logistical regression analysis after adjusting for CCI and the diagnosis of bronchiectasis. The regression was further stratified by age, gender, CCI, and bronchiectasis. The significance of modification effect by the covariate used to stratify patients for TB or NTM infection-associated SS risk was
investigated by estimating the p-value of the coefficient associated with the product of each indicator of the covariate and the indicator of TB or NTM infection using the Wald test. All data was analyzed using statistical software version 9.3 (SAS Institute, Inc., Cary, NC, USA). A p-value < 0.05 was considered statistically significant.

**Results**

**Characteristics of the study population**

A total of 5,751 SS cases and 86,265 matched non-SS controls were assessed (see S1 Dataset for details). We found that SS cases had a higher CCI (0.5±0.9 vs. 0.4±1.0, p<0.001) and were more likely to have bronchiectasis (4.1% vs. 1.3%, p<0.001), TB infection (1.0% vs. 0.5%, p<0.001) and NTM infection (0.1% vs. <0.1%, p< 0.001) compared with controls (Table 1). Additionally, the mean interval between diagnosis of NTM and TB in SS group was 2.1±2.2 and 3.4±2.5 years respectively, while those in control group was 2.9±1.4 and 3.8±2.4 years respectively.

**Association between a history of mycobacteria infection and the risk of Sjögren’s syndrome**

A conditional logistic regression model, adjusted for CCI and bronchiectasis, found that, compared with non-SS controls, SS cases were more likely to have a history of mycobacterial infection (aOR 1.36, 95% CI 1.03–1.80), diagnosis of bronchiectasis (aOR 2.74, 95% CI 2.36–3.18), and CCI ≥1 (aOR 1.83, 95% CI 1.71–1.94) (Table 2). To address the distinct association of SS with TB or NTM infection, we hence classified mycobacterial infections as either TB or NTM infection, and found a markedly high association between a history of NTM infection and the

| Table 1. Demographic data and clinical characteristics of patients. | Non-SS controls (n = 86,265) | SS cases (n = 5,751) | p-value |
| --- | --- | --- | --- |
| **Age, years** | 55±14 | 55±14 | 1 |
| **Age group** | | | |
| ≤40 years | 12,945 (15.0) | 863 (15.0) | 1 |
| 40–65 years | 51,660 (59.9) | 3,444 (59.9) | 1 |
| ≥65 years | 21,660 (25.1) | 1,444 (25.1) | 1 |
| **Gender** | | | |
| Female | 75,765 (87.8) | 5,051 (87.8) | 0.4±1.0 | 0.5±0.9 | <0.001 |
| Male | 10,500 (12.2) | 700 (12.2) | 1 |
| **CCI group** | | | |
| 0 | 66,918 (77.6) | 3,848 (66.9) | 19,347 (22.4) | 1,903 (33.1) |
| ≥1 | 1,157(1.3) | 235 (4.1) | <0.001 |
| **Bronchiectasis** | | | |
| Mycobacterial infection | 468 (0.5) | 61 (1.1) | <0.001 |
| NTM infection | 3 (0.0) | 4 (0.1) | <0.001 |
| Interval between NTM diagnosis and SS, years | 2.9±1.4 | 2.1±2.2 | 0.601 |
| TB infection | 465 (0.5) | 57 (1.0) | <0.001 |
| Interval between TB diagnosis and SS, years | 3.8±2.4 | 3.4±2.5 | 0.233 |

Abbreviations: SS, Sjögren’s Syndrome; CCI, Charlson comorbidity index; NTM, nontuberculous mycobacteria; TB, tuberculosis; NA, non-applicable. Percentages are enclosed in parentheses after each value unless otherwise indicated.

https://doi.org/10.1371/journal.pone.0176549.t001
risk of SS (aOR 11.24, 95% CI 2.37–53.24), whereas the correlation between a history of TB infection and SS risk did not reach statistical significance (aOR 1.29, 95% CI 0.97–1.71).

Subgroup analyses

In subgroup analyses, the association between the risk of SS and a history of mycobacteria infection, TB infection or NTM infection remained statistically significant among patients aged between 40 and 65 years, female patients, those with CCI = 0, and those without bronchiectasis (Table 3). Of note, the association between NTM infection and SS risk was strongest among those aged 40–65 years (aOR 39.24, 95% CI 3.97–387.75), followed by those without bronchiectasis (aOR 37.98, 95% CI 3.83–376.92).

Long treatment course in subjects with NTM infection

Table 4 details the medication history in subjects with NTM infection. As expected, all of the seven subjects with NTM infection underwent the clarithromycin-containing regimen, except for one subject (subject 4) who might be intolerant of clarithromycin and was treated mainly with moxifloxacin and doxycycline (Table 4). The treatment duration was quite long in

| Table 2. Unadjusted and adjusted odds ratios for the association between variables and the risk of Sjogren’s syndrome. |
|-----------------------------------------------------------|
| **Univariate analysis** | **Multivariable A** | **Multivariable B** |
|-------------------------|---------------------|---------------------|
| **Mycobacterial infection** | OR (95% CI) | aOR (95% CI) | aOR (95% CI) |
| NTM infection | 1.98 (1.51–2.59) | 1.36 (1.03–1.80) | |
| TB infection | 20.00 (4.48–89.36) | 11.24 (2.37–53.24) | |
| CCI >1 | 1.89 (1.77–2.01) | 1.83 (1.71–1.95) | 1.83 (1.71–1.94) |
| Bronchiectasis | 3.19 (2.76–3.69) | 2.74 (2.37–3.18) | 2.74 (2.36–3.18) |

*NTM and TB infection were integrated into the mycobacterial infection in model A and seen as independent variables in model B. Abbreviations: OR, odds ratio; CI: confidence intervals; NTM, nontuberculous mycobacteria; TB, tuberculosis; CCI, Charlson comorbidity index.

https://doi.org/10.1371/journal.pone.0176549.t002

| Table 3. Stratified analyses for the association between mycobacterial infection and risk of Sjogren’s syndrome. |
|-----------------------------------------------------------|
| **Mycobacterial infection** | **TB infection** | **NTM infection** |
|-------------------------|---------------------|---------------------|
| **Age group** | OR (95%CI) | p* | OR (95%CI) | p* | OR (95%CI) | p* |
| <40 years | 2.08 (0.77–5.61) | 0.085 | 2.08 (0.77–5.61) | 0.140 | — | — |
| 40–65 years | 1.81 (1.21–2.70) | 0.481 | 1.62 (1.07–2.47) | 0.092 | 39.24 (3.97–387.75) | — |
| ≥65 years | 1.02 (0.67–1.56) | 1.00 (0.65–1.54) | 2.45 (0.22–27.22) | — | — | — |
| **Gender** | 0.342 | 0.085 | 0.481 | 0.140 | — | — |
| Female | 1.51 (1.10–2.08) | 0.668 | 1.39 (1.00–1.94) | 1.141 | 2.45 (0.22–27.22) | — |
| Male | 0.99 (0.56–1.74) | 0.99 (0.56–1.74) | 0.99 (0.56–1.74) | 0.99 (0.56–1.74) | — | — |
| **CCI group** | 0.008 | 0.013 | >999 (—) | >999 (—) | >999 (—) | >999 (—) |
| 0 | 2.26 (1.46–3.47) | 0.008 | 2.07 (1.33–3.24) | 0.092 | >999 (—) | >999 (—) |
| >1 | 1.09 (0.72–1.64) | 1.04 (0.68–1.59) | 4.17 (0.36–48.98) | 1.04 (0.68–1.59) | 4.17 (0.36–48.98) | 4.17 (0.36–48.98) |
| Bronchiectasis | 0.072 | 0.097 | 0.072 | 0.097 | 0.072 | 0.097 |

*p for interaction. Abbreviations: NTM: nontuberculous mycobacteria; TB: tuberculosis; CCI: Charlson comorbidity index.

https://doi.org/10.1371/journal.pone.0176549.t003

https://doi.org/10.1371/journal.pone.0176549.0003
subjects with NTM infection, with 341.0±130.8 days. Taken together, these data support the idea that the identified patients with NTM infection in this study were not merely NTM colonization.

Discussion

To our knowledge, the present study is the first to investigate the association between mycobacterial infection and the risk of SS using a population-based dataset. The present study demonstrates an association between NTM infection and incident SS. Such association was remarkably high among subjects aged 40–65 years and those without bronchiectasis. Our results suggest the need for surveillance for SS in NTM infected patients, especially those who are 40–65 years of age and who did not have bronchiectasis, so as to diagnose and treat SS early. Possible explanations for the high association between NTM infection and SS risk as shown in this study include similar immune pathways, mycobacterium-initiated autoimmunity and reverse causality due to the insidious progression of SS.

First, both SS and NTM infections are apparently to occur in postmenopausal women, indicating potential shared immune mechanisms and a possible role of sex hormones in these two diseases [20–22]. Mavragani et al. reported increased circulating type I interferon (IFN) levels with upregulated type I IFN-inducible genes in salivary gland tissues of patients with SS [20]. Type I IFN has also been found recently to play a major role in the dysregulated inflammation of mycobacterial infection [23], making it a potential target for immune therapy, so-called host-directed therapy, aiming to alleviate the host-detrimental inflammation in mycobacterial infection [24]. Upregulated type I IFN may thus be one example of shared immunological pathways in these two highly correlated diseases. Furthermore, a low level of serum sex hormone, namely dehydroepiandrosterone (DHEA), has been identified in women with pulmonary Mycobacterium avium complex infection [25], while a lack of estrogen and DHEA has been found to result in increased apoptosis of the exocrine secretory cells in SS [21]. These mechanisms may at least partly explain the high correlation between NTM infection and SS development in postmenopausal women.

Second, dysregulated inflammation against an inert and relatively low-virulence mycobacterium has been found to play a crucial role in mycobacterial infections [26]. Autoimmunity has similarly been proposed to correlate with a dysregulated, non-resolving, and host-detrimental inflammation in mycobacterial infection [7, 27]. Some findings with regards to mycobacterium-related autoimmunity have been reported, including that anti-cyclic citrullinated peptide antibody was found in 37% of TB patients [28], and the anti-IFN-gamma autoantibody in subjects with disseminated NTM infection [29]. Sarcoidosis, an autoimmune disease without known autoantigen, maybe another piece of evidence linking autoimmunity

| Subjects with SS |  | Overall | Clarithromycin | Ethambutol | Rifampin | Isoniazid | Moxifloxacin | Doxycycline |
|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Subject 1        | 64               | 366             | 366             | 366             | 366             | 366             | 366             | 366             |
| Subject 2        | 78               | 455             | 427             | 329             | 455             | 455             | 455             | 455             |
| Subject 3        | 42               | 490             | 154             | 490             | 490             | 490             | 490             | 490             |
| Subject 4a       | 46               | 369             | 29              | 21              | 21              | 21              | 21              | 369             | 109             |

| Subjects without SS |  | Overall | Clarithromycin | Ethambutol | Rifampin | Isoniazid | Moxifloxacin | Doxycycline |
|---------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Subject 1           | 71               | 381             | 381             | 381             | 381             | 381             | 381             | 381             |
| Subject 2           | 88               | 186             | 186             | 186             | 186             | 186             | 186             | 186             |
| Subject 3           | 58               | 140             | 140             | 28              | 28              | 28              | 28              | 14              |

*aAlso received cefoxitin and rifabutin for 25 days. Abbreviations: NTM: nontuberculous mycobacteria; SS: Sjögren’s Syndrome.*
and mycobacteria, because of the indistinguishable granulomatous inflammation common to both sarcoidosis and mycobacterial infection [30]. Heat-shock protein has been implicated in the initiation of autoimmunity in TB infection [7]; however, the crucial causal factor to initiate autoimmunity in mycobacterial infection remains elusive at this point. In this study, we found a much higher correlation between NTM and SS than those between TB and SS; this finding might be explained by the high probability of exposure to environmental NTM and further support the possibility of infection-induced autoimmunity in NTM infection.

Third, SS is a disease with insidious progression [2, 3] and has an increased risk of infection including TB [10]. In this study, of the seven subjects with NTM infection and later diagnosed SS, three of them were diagnosed as SS within three months after NTM infection, indicating the potential co-existence of these two diseases, while the other four subjects were diagnosed as SS averagely 2.9 years after NTM infection. Therefore, among SS cases with a history of NTM infection, we cannot exclude the possibility that SS had developed before NTM infection. However, the significant association between NTM infection and newly diagnosed SS demonstrated in our study may suggest a need to survey the existence of SS for NTM infected patients.

Although the association between TB infection and SS risk did not reach statistical significance (aOR, 1.29; 95% CI, 0.97–1.71) among all study subjects, such association was significant in those with CCI = 0 (aOR, 2.07; 95% CI, 1.33–3.24). Of note, the modification effect by CCI for this association was also statistically significant (p-value for interaction = 0.013). Therefore, this finding suggests that mycobacterial infection might still be a risk factor for incident SS among individuals without any comorbidities used for CCI calculation.

There are limitations in this study that merit discussion. First, information of NTM species was lacking in this claim-based dataset. Therefore, we cannot assess the association between SS risk and specific NTM species in this study. However, we thought the data of this study merits further mechanistic studies. Second, given the fact that RA and SLE are associated with mycobacterial infection and SS [15], this study excluded patients with RA or SLE; therefore, the results cannot be applied to patients with RA- or SLE-related secondary SS. Third, the accuracy of diagnoses according to claims data is of concern. However, the regular check of the quality of claims data from all medical institutions by the BNHI has improved coding accuracy [31] and thus minimized bias due to misclassification. Also, the accuracy of SS diagnosis is of less concern since at least two qualified rheumatologists had validated the diagnosis before SS cases were issued a catastrophic illness certificate. The non-differential misclassification bias related to TB or NTM diagnosis in both groups is always biased toward the null, leading to underestimating the association of SS risk with TB or NTM. The prolonged study period 2007–2012 could be another concern; however, the diagnosis and treatment was consistent during the study period. Briefly, Taiwan Center for Disease Control (CDC) has conducted the external quality assessment of clinical mycobacteriology laboratories since 2007 [32], and the treatment of TB in Taiwan has been standardized since 2005 with directly observed therapy-short course (DOTS) by Taiwan CDC [33]. Additionally, in subjects with NTM infection, the average duration of clarithromycin-use was 276±129 days, and such a long-course clarithromycin-contained regimen was in accordance with the NTM treatment guideline published in 1997 and the revised edition published in 2007 [34, 35].

**Conclusion**

In conclusion, using a nationwide, population-based dataset, this study revealed a significant association between NTM infection and the risk of SS, in particular among those aged 40–65 years and those without a history of bronchiectasis. We believed that these data might support
the need for screening for SS in patients with NTM infection, particularly among those aged 40–65 years and those without a history of bronchiectasis. More studies are warranted in the future to explore underlying mechanisms.

**Supporting information**

S1 Dataset. Data of the SS cases and non-SS controls. (XLSX)

**Acknowledgments**

This study is based in part on data from the National Health Insurance Research Database provided by the National Health Insurance Administration, Ministry of Health and Welfare and managed by National Health Research Institutes (Registered number 101095, 102148). The interpretation and conclusions contained herein do not represent those of National Health Insurance Administration, Ministry of Health and Welfare or National Health Research Institutes. The authors thank for the statistical work by Biostatistics Task Force of Taichung Veterans General Hospital, Taichung, Taiwan, ROC.

**Author Contributions**

Conceputalization: HHC WCC.

Data curation: HHC CHL.

Formal analysis: HHC TLL WCC YMC.

Funding acquisition: HHC.

Investigation: HHC TLL WCC YMC.

Methodology: HHC TLL WCC YMC DYC.

Project administration: HHC WCC.

Resources: HHC CHL.

Software: HHC CHL.

Validation: HHC CHL.

Writing – original draft: HHC WCC.

Writing – review & editing: DYC WCC TLL HHC.

**References**

1. Peri Y, Agmon-Levin N, Theodor E, Shoenfeld Y. Sjogren’s syndrome, the old and the new. Best practice & research Clinical rheumatology. 2012; 26(1):105–17.

2. Gary S. Firestein, Ralph C. Budd, Sherine E Gabriel, Iain B McInnes, O’Dell JR. Kelley’s Textbook of Rheumatology2013. 1169–91

3. Olate S, Munoz D, Neumann S, Pozzer L, Cavalieri-Pereira L, de Moraes M. A descriptive study of the oral status in subjects with Sjogren’s syndrome. International journal of clinical and experimental medicine. 2014; 7(4):1140–4. PubMed Central PMCID: PMC4057875. PMID: 24955196

4. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjogren’s syndrome. Autoimmunity reviews. 2010; 9(5):A305–10. https://doi.org/10.1016/j.autrev.2009.11.004 PMID: 19903539

5. Cronan MR, Beerman RW, Rosenberg AF, Saelens JW, Johnson MG, Oehler SH, et al. Macrophage Epithelial Reprogramming Underlies Mycobacterial Granuloma Formation and Promotes Infection.
6. Elkington P, Tebruegge M, Mansour S. Tuberculosis: An Infection-Initiated Autoimmune Disease? Trends in immunology. 2016.

7. Shoda H, Hanata N, Sumimoto S, Okamura T, Fujiy K, Yamamoto K. Immune responses to Mycobacterial heat shock protein 70 accompany self-reactivity to human BiP in rheumatoid arthritis. Scientific reports. 2016; 6:22486. PubMed Central PMCID: PMC4772543. https://doi.org/10.1038/srep22486 PMID: 26927756

8. Mavragani CP, Fragoulis GE, Moutsopoulos HM. Endocrine alterations in primary Sjogren’s syndrome: an overview. Journal of autoimmunity. 2012; 39(4):354–8. https://doi.org/10.1016/j.jaut.2012.05.011 PMID: 2269158

9. Sandhya P, Kurien BT, Danda D, Sceifeld RH. Update on Pathogenesis of Sjogren’s syndrome. Current rheumatology reviews. 2016.

10. Mirsaeidi M, Sadikot RT. Gender susceptibility to mycobacterial infections in patients with non-CF bronchiectasis. International journal of mycobiology. 2015; 4(2):92–6. PubMed Central PMCID: PMC4470303. https://doi.org/10.1016/j.ijmyco.2015.05.002 PMID: 26097805

11. Chang YS, Liu C, Ou SM, Hu YW, Chen TJ, Lee HT, et al. Tuberculosis infection in primary Sjogren’s syndrome: a nationwide population-based study. Clinical rheumatology. 2014; 33(3):377–83. https://doi.org/10.1007/s10067-013-2408-y PMID: 24170112

12. National Health Insurance Annual Report 2014–2015. : National Health Insurance Administration, Ministry of Health and Welfare, Taiwan, R.O.C.; 2014.

13. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Annals of the rheumatic diseases. 2002; 61(6):554–8. PubMed Central PMCID: PMC1754137. https://doi.org/10.1136/ard.61.6.554 PMID: 12006334

14. Lo HY, Yang SL, Chou P, Chuang JH, Chiang CY. Completeness and timeliness of tuberculosis notification in Taiwan. BMC Public Health. 2011; 11:915. PubMed Central PMCID: PMC3260335. https://doi.org/10.1186/1471-2458-11-915 PMID: 22151346

15. Liao TL, Lin CH, Shen GH, Chang CL, Lin CF, Chen DY. Risk for Mycobacterial Disease among Patients with Rheumatoid Arthritis, Taiwan, 2001–2011. Emerging infectious diseases. 2015; 21 (8):1387–95. PubMed Central PMCID: PMC4517709. https://doi.org/10.3201/eid2108.141846 PMID: 26196158

16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of clinical epidemiology. 1992; 45(6):613–9. PMID: 1607900

17. Chu H, Zhao L, Xiao H, Zhang Z, Zhang J, Gui T, et al. Prevalence of nontuberculous mycobacteria in patients with bronchiectasis: a meta-analysis. Archives of medical science: AMS. 2014; 10(4):661–8. PubMed Central PMCID: PMC4175767. https://doi.org/10.5114/aoms.2014.44857 PMID: 25276148

18. Jordan TS, Spencer EM, Davies P. Tuberculosis, bronchiectasis and chronic airflow obstruction. Respirology. 2010; 15(4):623–8. https://doi.org/10.1111/j.1440-1843.2010.01749.x PMID: 20409028

19. Ko JM, Kim KJ, Park SH, Park HJ. Bronchiectasis in active tuberculosis. Acta radiologica. 2013; 54(4):412–7. https://doi.org/10.1177/0284185113475796 PMID: 23390158

20. Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjogren’s syndrome. Journal of autoimmunity. 2010; 35(3):225–31. https://doi.org/10.1016/j.jaut.2010.06.012 PMID: 20674271

21. Konttinen YT, Fuellen G, Bing Y, Porola P, Stegaaev V, Trokovic N, et al. Sex steroids in Sjogren’s syndrome. Journal of autoimmunity. 2010; 35(3):225–31. https://doi.org/10.1016/j.jaut.2010.06.012 PMID: 22300712

22. Chan ED, Iseman MD. Underlying host risk factors for nontuberculous mycobacterial lung disease. Seminars in respiratory and critical care medicine. 2013; 34(1):110–23. https://doi.org/10.1055/s-0033-133573 PMID: 23460011

23. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature. 2014; 511(7507):99–103. PubMed Central PMCID: PMC4809146. https://doi.org/10.1038/nature13489 PMID: 24990750

24. Friedland JS. Targeting the inflammatory response in tuberculosis. The New England journal of medicine. 2014; 371(14):1354–6. https://doi.org/10.1056/NEJMcr1408663 PMID: 25271609

25. Danley J, Kwiat R, Peterson DD, Sendecki J, Vaughn B, Nakisbendi K, et al. Normal estrogen, but low dehydroepiandrosterone levels, in women with pulmonary Mycobacterium avium complex. A preliminary study. Annals of the American Thoracic Society. 2014; 11(6):908–14. https://doi.org/10.1513/AnnalsATS.201312-422OC PMID: 24963545
26. Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, et al. Type I and II interferon signatures in Sjogren’s syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren’s related lymphomagenesis. Journal of autoimmunity. 2015; 63:47–58. PubMed Central PMCID: PMC4564326. https://doi.org/10.1016/j.jaut.2015.07.002 PMID: 26183766

27. Root-Bernstein R, Fairweather D. Complexities in the relationship between infection and autoimmunity. Current allergy and asthma reports. 2014; 14(1):407. PubMed Central PMCID: PMC3926441. https://doi.org/10.1007/s11882-013-0407-3 PMID: 24352912

28. Kakumanu P, Yamagata H, Sobel ES, Reeves WH, Chan EK, Satoh M. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis and rheumatism. 2008; 58(6):1576–81. PubMed Central PMCID: PMC3621955. https://doi.org/10.1002/art.23514 PMID: 18512773

29. Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw PA, et al. Adult-onset immunodeficiency in Thailand and Taiwan. The New England journal of medicine. 2012; 367(8):725–34. PubMed Central PMCID: PMCPMC4190026. https://doi.org/10.1056/NEJMoa1111160 PMID: 22913682

30. Maertzdorf J, Weiner J 3rd, Mollenkopf HJ, Network TB, Bauer T, Prasse A, et al. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A. 2012; 109(20):7853–8. PubMed Central PMCID: PMCPMC3356621. https://doi.org/10.1073/pnas.112072109 PMID: 22547807

31. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far. Health affairs. 2003; 22(3):61–76. PMID: 12757273

32. Jou R, Chiang CY, Yu CY, Wu MH. Proficiency of drug susceptibility testing for Mycobacterium tuberculosis in Taiwan. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2009; 13(9):853–8. PubMed Central PMCID: PMCPMC3621955. https://doi.org/10.1002/art.23514 PMID: 18512773

33. Chien JY, Lai CC, Tan CK, Chien ST, Yu CJ, Hsueh PR. Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan. The Journal of antimicrobial chemotherapy. 2013; 68(8):1910–6. https://doi.org/10.1093/jac/dkt103 PMID: 23580558

34. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. American journal of respiratory and critical care medicine. 2007; 175(4):367–416. https://doi.org/10.1164/rccm. 200604-571ST PMID: 17277290

35. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. American journal of respiratory and critical care medicine. 1997; 156(2 Pt 2):S1–25.